First-generation EGFR inhibitors, such as erlotinib and gefitinib, initially showed effectiveness in treating NSCLC but eventually developed resistance due to the emergence of the T790M mutation after a median response duration of 12 months (11). This evidence concerns the gene EGFR and non-small cell lung carcinoma.